Drugs / QLH12016
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05973149 | Aug 2023 → Aug 2025 | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07198633 | Nov 2025 → Dec 2026 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07104110 | Oct 2025 → Oct 2027 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLH12016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07104110 ↗ |
| Modality | Other / unclassified | “oral AR PROTAC” NCT07104110 ↗ |
| Route | Oral | “oral AR PROTAC” NCT07104110 ↗ |
| Target | AR | “oral AR PROTAC” NCT07104110 ↗ |